Highlights

  • Singular Health Group (ASX:SHG) reported FY26 Revenue growth supported by paid deployments of its 3DICOM medical imaging platform.
  • The company received FDA 510(k) clearance for its browser-based 3DICOM MD Cloud platform during FY26.
  • A US primary care deployment has expanded to 750 licences, providing an early commercial reference point.
  • Contract conversion, Recurring Revenue growth and expansion across US healthcare networks remain key areas to monitor.

Singular Health Group (ASX:SHG) is transitioning from healthcare technology development towards commercial deployment of its 3DICOM medical imaging platform.

The company reported significant percentage-based revenue growth during FY26, although the absolute revenue base remains early stage. The key focus now is whether initial deployments and healthcare partnerships can develop into repeatable recurring revenue streams.

Latest Development

In its FY26 Annual Report released in late August 2026, Singular Health Group (ASX:SHG) reported revenue of A$1,428,231 for the year ended 30 June 2026, compared with A$235,393 in the prior year.

The net loss remained broadly unchanged at A$6.34 million compared with A$6.38 million previously.

The company did not declare a dividend.

A major milestone during the year was FDA 510(k) clearance for the browser-based 3DICOM MD Cloud platform.

The clearance expanded supported imaging formats across CT, MRI, PET, X-ray and ultrasound applications.

Singular Health also reported holding ISO 27001, HIPAA and SOC 2 Type II certifications, while HITRUST certification remains in progress.

Company Overview

Singular Health Group (ASX:SHG) develops the 3DICOM platform, a suite of healthcare imaging and interoperability solutions.

The platform is designed to improve access, viewing and sharing of medical imaging data across different healthcare environments.

The product suite includes:

  • Clinical imaging tools for healthcare providers.
  • Patient-facing imaging portals.
  • Education-focused applications.
  • Artificial intelligence-assisted features.

The company's commercial focus is primarily the United States healthcare market, particularly primary care providers, health plans, education institutions and government imaging infrastructure.

Recent Developments

A key commercial relationship has developed with Provider Network Solutions, where deployment expanded to 750 3DICOM MD licences across primary care providers.

Singular Health received a contracted US$500,000 licence payment from the relationship in April 2026.

Life Radiology in Florida had more than 230 patients enrolled, while a statewide imaging repository initiative in Florida was also progressing.

The company has also advanced education applications, with a Miami-Dade County Public Schools pilot prepared for its first student cohort in September 2026.

Discussions with health plan Triple-S in Puerto Rico had reached an advanced stage, while the company also entered a non-binding memorandum of understanding with Stellae Health to explore a pilot programme across primary care practices.

Financial and Operational Position

At 30 June 2026, Singular Health Group (ASX:SHG) held A$2.36 million in cash and A$7.70 million in term deposits.

Net Assets stood at A$10.54 million, while basic loss per share was 2.03 cents.

During the June 2026 quarter, customer receipts reached A$721,000, including the Provider Network Solutions payment.

Net operating cash outflow was A$857,000, while direct operating costs totalled A$1.71 million.

Staff costs were the largest direct Operating Expense at A$841,000.

Based on available funding and operating assumptions, the company estimated its funding runway at approximately 11.75 quarters.

What Investors May Watch Next

The start of the Miami-Dade student cohort in September 2026 represents one of the next scheduled milestones.

Investors may also monitor whether discussions with Triple-S and the Stellae Health memorandum progress into binding commercial agreements.

Expansion beyond the initial 750 Provider Network Solutions licences will be another important indicator of whether the platform can scale within healthcare networks.

Progress on HITRUST certification, Patent filings and broader US healthcare adoption will also provide insight into the company's commercial development.

Risks

Singular Health Group (ASX:SHG) remains an early-stage healthcare software company with relatively small revenue compared with operating costs.

FY26 revenue was supported partly by a significant individual licence payment, meaning future revenue growth will depend on converting deployments into recurring contracts.

The company continues to record annual losses, and its funding runway relies on continued commercial progress and disciplined expenditure.

Healthcare software sales can involve lengthy procurement cycles, particularly in the US market.

Pilot programmes and memoranda of understanding do not guarantee future revenue, and successful adoption depends on healthcare-provider engagement.

Key Takeaways

Singular Health Group (ASX:SHG) has progressed from technology development towards early commercial adoption, supported by FDA clearance, paid deployments and growing healthcare partnerships.

The key challenge now is converting these early relationships into repeatable recurring revenue.

The next phase will likely be defined by licence expansion, contract conversions and evidence that the 3DICOM platform can achieve broader adoption across US healthcare networks.